Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Lebrikizumab, a monoclonal antibody that inhibits an interleukin named IL-13, is especially promising in treatment of this disease. Having been in development by Almirall and Eli Lilly and Company ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Lebrikizumab also works in a different way from Dupixent, targeting IL-13, and Almirall hopes that Sanofi’s innovation has cleared the way for other injected rivals. Almirall’s strategy for ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Apogee Therapeutics, Inc. (NASDAQ: APGE) has announced the dosing of the first patient in the part B portion of the phase 2 ...

POD is an inflammatory skin disease, appearing as erythematous papules, vesicles, or pustules localized around the mouth, nose, and eyes. A diagnosis of POD should be considered with young female ...

WE REPORT FOUR CASES of eyelid dermatitis in women who were patch-tested with the standard tray of 65 allergens and their own products. All four women were found to be allergic to their own ...